Key result
Lower baseline IGF1 and higher IGFBP1 predict incident diabetes in prediabetes patients undergoing lifestyle intervention.
Why the study?
Some individuals develop type 2 diabetes mellitus despite significant metabolic improvements through lifestyle intervention, raising the question of whether IGF1 and its binding proteins predict diabetes onset.
Do baseline levels of IGF1 and IGFBP1 predict the onset of type 2 diabetes mellitus in high-risk prediabetes patients undergoing lifestyle intervention?
RCT (n=414)
randomized
Do baseline levels of IGF1 and IGFBP1 predict the onset of type 2 diabetes mellitus in high-risk prediabetes patients undergoing lifestyle intervention?
Effect estimate: HR 0.991 for IGF1; HR 1.061 for IGFBP1
p-value: p=0.003 for IGF1; 0.002 for IGFBP1
Lower IGF1 and higher IGFBP1 levels in prediabetic patients predict the onset of type 2 diabetes despite lifestyle interventions, suggesting an underlying impairment of beta-cell function.
May refine diabetes risk stratification in prediabetes despite lifestyle intervention; leaves open causal role and need for prospective validation.
Objectives: Some individuals develop type 2 diabetes mellitus (T2DM) despite significant metabolic improvements through lifestyle intervention. We tested the hypotheses that insulin growth factor 1 (IGF1) and its binding proteins 1 and 2 predict the onset of T2DM in prediabetes patients and determine the capacity for metabolic regeneration. Design: We measured fasting serum IGF1, insulin growth factor-binding protein 1 (IGFBP1) and IGFBP2 in three randomized controlled lifestyle intervention trials, covering at least 1 year of intervention period and 1 year of additional follow-up. Methods: Within a sample of 414 high-risk prediabetes patients (58% women; 28-80 years), we analyzed fasting serum concentrations of IGF1, IGFBP1 and IGFBP2 in relation to diabetes incidence and metabolic parameters over 2 years. Three hundred and forty-five subjects finished the first year of intervention. Results: The interventions significantly improved body weight (BMI: -3.24%, P < 0.001), liver fat (-36.8%, P < 0.001), insulin sensitivity (IS) (homeostatic model assessment-insulin resistance: -6.3%, P < 0.001) and insulin secretion (disposition index: +35%, P < 0.001) in the cohort. Fourteen percent developed T2DM within 2 years. Mean IGFBP1 levels at baseline were lower in prediabetes compared to a healthy population. Also, prediabetes patients with obesity and nonalcoholic fatty liver disease had lower IGFBP1. Those with impaired glucose tolerance had higher IGFBP1 compared to those with only impaired fasting glucose. Baseline IGF1 was lower (122.5 vs 146.6 µg/L) and IGFBP1 was higher (3.32 vs 2.09 µg/L) in subjects who developed T2DM (n = 57), resulting in a significant prediction of diabetes incidence (hazard ratio (HR) IGF1: 0.991 µg/L, P = 0.003; HR IGFBP1: 1.061 µg/L, P = 0.002). This translates into a 20% and 9% difference in T2DM incidence for IGF1 and IGFBP1, respectively. Despite reduced weight, visceral fat and hepatic fat in response to 1 year of lifestyle intervention, those who developed T2DM had not improved insulin sensitivity, glucose tolerance or IGFBP1. Conclusions: Lower IGF1 and higher IGFBP1 in prediabetes predicted the incidence of T2DM, indicating an impairment of beta-cell function, which explains the unresponsiveness to lifestyle intervention.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2022) conducted an RCT in Prediabetes (n=414). Lifestyle intervention was evaluated on Diabetes incidence (HR 0.991 for IGF1; HR 1.061 for IGFBP1, p=0.003 for IGF1; 0.002 for IGFBP1). Lower baseline IGF1 (HR 0.991, P=0.003) and higher IGFBP1 (HR 1.061, P=0.002) predicted the 2-year incidence of type 2 diabetes in prediabetes patients undergoing lifestyle intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: